{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T09:08:38Z","timestamp":1751533718434,"version":"3.37.3"},"reference-count":24,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"accepted":{"date-parts":[[2020,9,27]]},"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Postexposure prophylaxis (PEP) is a recommended public health intervention after a sexual assault to prevent HIV infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective case-control study on how use of a single-tablet regimen (STR) of elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate (Stribild) affected adherence to PEP and attendance of a follow-up visit to the STI clinic compared with those who received a multitablet regimen (MTR). Data from sexual assault victims consulting for PEP were prospectively recorded between January 2011 and December 2017. Data were systematically collected on patient demographics, time of medical contact, source risk factors, type of exposure, attendance to follow-up visit, reported completion of PEP and adherence based on pharmacy records.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 422 patients received PEP following a sexual assault, of whom 52% had documented completion of a 28-day PEP regimen and 71% attended a follow-up clinic visit. Patients who received an elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate (EVG\/COBI\/FTC\/TDF)-based STR had a similar likelihood of attending their first follow-up visit (OR: 0.97; 95% CI: 0.64 to 1.48, p=0.90) but were more likely to complete the PEP regimen (OR: 1.70; 95% CI: 1.16 to 2.50, p=0.007). After adjusting for confounders, those who were prescribed an STR regimen were more likely to complete the PEP regimen (OR: 1.66, 95%\u2009CI: 1.09 to 2.53, p=0.019) than those who were prescribed an MTR such as stavudine\/lamivudine\/lopinavir\/ritonavir or zidovudine\/lamivudine\/indinavir\/ritonavir.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Sexual assault victims who were prescribed an STR based on EVG\/COBI\/FTC\/TDF were more likely to complete PEP than those who were prescribed an MTR.<\/jats:p><\/jats:sec>","DOI":"10.1136\/sextrans-2020-054714","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T21:27:02Z","timestamp":1603747622000},"page":"329-333","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Single-tablet regimen of emtricitabine\/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims"],"prefix":"10.1136","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3840-0491","authenticated-orcid":false,"given":"Stefano","family":"Malinverni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floriane","family":"B\u00e9doret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Bartiaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"De Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Libois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"key":"2024092104001026000_97.5.329.1","doi-asserted-by":"crossref","first-page":"S856","DOI":"10.1093\/cid\/civ786","article-title":"Sexual assault and sexually transmitted infections in adults, adolescents, and children","volume":"61 Suppl 8","author":"Se\u00f1a","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024092104001026000_97.5.329.2","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199711203372101","article-title":"A Case\u2013Control study of HIV seroconversion in health care workers after percutaneous exposure","volume":"337","author":"Cardo","year":"1997","journal-title":"N Engl J Med Overseas Ed"},{"key":"2024092104001026000_97.5.329.3","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.5.4265-4273.1998"},{"key":"2024092104001026000_97.5.329.4","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2011-050371"},{"key":"2024092104001026000_97.5.329.5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0142534","article-title":"Adherence to post-exposure prophylaxis (PEP) and incidence of HIV seroconversion in a major North American cohort","volume":"10","author":"Thomas","year":"2015","journal-title":"PLoS One"},{"key":"2024092104001026000_97.5.329.6","unstructured":"Behrens G , Pozniak A , Massimo Puoti JMM . Guidelines version 9.1. European AIDS clinical Society (EACS), 2018. Available: http:\/\/www.eacsociety.org\/files\/2018_guidelines-9.1-english.pdf. [Accessed 30 Sep 2019]."},{"key":"2024092104001026000_97.5.329.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7999"},{"key":"2024092104001026000_97.5.329.8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007701"},{"key":"2024092104001026000_97.5.329.9","doi-asserted-by":"publisher","DOI":"10.1126\/science.1248707"},{"key":"2024092104001026000_97.5.329.10","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31824a03b8"},{"key":"2024092104001026000_97.5.329.11","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1330-0"},{"key":"2024092104001026000_97.5.329.12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17843286.2018.1428506","article-title":"Belgian guidelines for non-occupational HIV post-exposure prophylaxis 2017","volume":"73","author":"Libois","year":"2018","journal-title":"Acta Clin Belg"},{"key":"2024092104001026000_97.5.329.13","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000505"},{"key":"2024092104001026000_97.5.329.14","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1093\/jac\/dkx246","article-title":"Tenofovir disoproxil fumarate\/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis","volume":"72","author":"Inciarte","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2024092104001026000_97.5.329.15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/QAI.0000000000001440","article-title":"Optimal HIV postexposure prophylaxis regimen completion with single tablet daily Elvitegravir\/Cobicistat\/Tenofovir disoproxil Fumarate\/Emtricitabine compared with more frequent dosing regimens","volume":"75","author":"Mayer","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024092104001026000_97.5.329.16","unstructured":"Malinverni S , Libois A , Mols P . HIV Drug Therapy. In: Compliance of fixed-dose single tablet EVG\/COBI\/FTC\/TDF (Stribild) regimen versus LPV\/r\/d4T\/3TC for PEP in sexual assault victims: a retrospective sequential period study. Glasgow, 2016."},{"key":"2024092104001026000_97.5.329.17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1010-7"},{"key":"2024092104001026000_97.5.329.18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ511"},{"key":"2024092104001026000_97.5.329.19","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/QAD.0000000000001447","article-title":"Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV postexposure prophylaxis in gay and bisexual men","volume":"31","author":"McAllister","year":"2017","journal-title":"AIDS"},{"key":"2024092104001026000_97.5.329.20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jinf.2017.10.008","article-title":"Adherence to HIV post-exposure prophylaxis: a multivariate regression analysis of a 5 years prospective cohort","volume":"76","author":"Malinverni","year":"2018","journal-title":"J Infect"},{"key":"2024092104001026000_97.5.329.21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1089\/apc.2019.0080","article-title":"Predictors of adherence to HIV post-exposure prophylaxis and retention in care after an episode of sexual violence in Brazil","volume":"33","author":"Nisida","year":"2019","journal-title":"AIDS Patient Care STDS"},{"key":"2024092104001026000_97.5.329.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2012.01034.x"},{"key":"2024092104001026000_97.5.329.23","doi-asserted-by":"publisher","DOI":"10.1080\/09540121.2010.484457"},{"key":"2024092104001026000_97.5.329.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b515"}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2020-054714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T11:01:41Z","timestamp":1726916501000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2020-054714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,7,19]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1136\/sextrans-2020-054714"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2020-054714","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"type":"print","value":"1368-4973"},{"type":"electronic","value":"1472-3263"}],"subject":[],"published":{"date-parts":[[2020,10,26]]}}}